Abstract
Background
Diffuse large B cell lymphoma (DLBCL) is divided into Germinal center B-cell like (GCB) subtype and non-GCB by the Hans algorithm and non-GCB is known to be associated with unfavorable prognosis. Therefore, we tried to compare the difference of clinical parameters between GCB and non-GCB DLBCL subtypes.
Methods
We retrospectively analyzed DLBCL patients in the Asan Medical Center's lymphoma database from January 2001 to December 2014. We selected 796 patients who received first line R-CHOP chemotherapy and whose cell-of-origin can be classified by the Hans algorithm.
Results
Among the 796 patients, 261 (32.8%) were in the GCB subtype and 535 (67.2%) were in the non-GCB group by the Hans algorithm. ECOG PS≥2, increased β2M (β2-microglobulin), increased LDH, Ann Arbor stage 3-4, high NCCN IPI and GELTAMO IPI stage were associated with non-GCB type. There was borderline significant difference in disease-free survival (DFS) for patients in the GCB and non-GCB cohorts (p=.07).
Conclusions
Non-GCB subtype DLBCL had relatively unfavorable prognostic factors than GCB DLBCL. Such as ECOG PS≥2, increased β2M (β2-microglobulin), increased LDH, Ann Arbor stage 3-4, high NCCN IPI and GELTAMO IPI stage were more distributed in non-GCB DLBCL.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal